Plain-English translation of NCT07656857 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new surgical technique for people with drug-resistant epilepsy — seizures that don't stop even with multiple seizure medications. During brain surgery to remove the seizure-causing area, surgeons will use a special high-density flexible micro-electrocorticography (μECoG) device — a thin, sensitive tool that maps electrical activity in the brain with exceptional precision. The study aims to see whether this advanced brain mapping helps surgeons identify and remove exactly the right area, leading to better outcomes and fewer seizures after surgery.
Many people with focal epilepsy don't improve with medications alone and need brain surgery to remove the seizure-causing area. However, identifying the exact area to remove during surgery is challenging, and current methods don't always lead to good outcomes. This trial exists to test whether the advanced brain mapping tool can help surgeons be more precise, potentially improving seizure control and quality of life for patients.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will undergo epilepsy surgery at Beijing Tiantan Hospital with the advanced brain mapping device used during the procedure to guide the surgeon's resection. The surgical team will use the high-density flexible μECoG tool to precisely identify the seizure-causing area before removal. You will then be followed after surgery to track your seizure control and recovery, with assessments to evaluate how well the treatment worked compared to historical data from patients who had surgery without this advanced mapping technology.
AI-generated summary from trial data · Aug 21, 2026 · Not medical advice
China
Sponsor
Beijing Tiantan Hospital
Collaborators
Beijing Fengtai Hospital, Peking University First Hospital
Enrollment target
~85 participants
Started
September 2026
Primary completion
July 2028
Age range
3 Years – 60 Years
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kai Zhang Dr
Beijing Tiantan Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.